StrataXRT for the prevention of acute radiation dermatitis in breast cancer: a systematic review and meta-analysis of randomized controlled trials

Shing Fung Lee, Saba Shariati, Saverio Caini, Henry Wong, Adrian W. Chan, Milena Gojsevic, Mami Ogita, Jason C. Ye, David Chia, Michael Chao, Ki Hoon Sung, Samantha K.F. Kennedy, Thenugaa Rajeswaran, Corina van den Hurk, Julie Ryan Wolf, Raymond J. Chan, Tara Behroozian, Pierluigi Bonomo, Edward Chow

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

PURPOSE: To evaluate the overall efficacy of StrataXRT, a topical gel dressing, in preventing acute radiation dermatitis (RD) in breast cancer patients undergoing radiotherapy (RT). 

METHODS: A systematic search was conducted on April 25, 2023 in Ovid MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. Randomized controlled trials (RCTs) assessing the effectiveness of StrataXRT in preventing acute RD in breast cancer patients undergoing adjuvant RT to the breast or chest wall with or without regional nodes were included. Pooled incidence odds ratio (OR) and 95% confidence interval (CI) were calculated using a random-effects model, with analysis and forest plots generated in RevMan v5.4. 

RESULTS: The analysis included three RCTs with a total of 189 patients assessed using per-protocol analysis. Two RCTs compared StrataXRT to standard of care, while the third compared it with Mepitel film and was reported separately. In the former RCTs, the odds ratio (OR) for developing acute grade 3 RD favored StrataXRT at 0.05 (95% CI, 0.01-0.22; P < 0.0001). The OR for developing acute grades 2-3 RD was 0.32 (95% CI, 0.03-3.18; P = 0.33). The RCT comparing StrataXRT with Mepitel film showed insignificant ORs for grade 3 and grades 2-3 RD. One RCT reported significantly lower erythema index (P = 0.008) and melanin index (P = 0.015) in StrataXRT patients. The use of StrataXRT did not raise additional safety concerns. 

CONCLUSION: StrataXRT may help prevent severe acute RD in breast cancer RT patients. Further high quality, large-scale studies are needed to confirm these findings.

Original languageEnglish
Article number515
Number of pages10
JournalSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Volume31
Issue number9
DOIs
Publication statusPublished - 9 Aug 2023

Keywords

  • Acute radiation dermatitis
  • Breast cancer
  • Patient reported outcomes, meta-analysis
  • Skin toxicity
  • StrataXRT
  • Systematic review

Fingerprint

Dive into the research topics of 'StrataXRT for the prevention of acute radiation dermatitis in breast cancer: a systematic review and meta-analysis of randomized controlled trials'. Together they form a unique fingerprint.

Cite this